STOCK TITAN

Dynavax Technolo - DVAX STOCK NEWS

Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.

Dynavax Technologies Corporation (DVAX) delivers innovative vaccine solutions through cutting-edge immunological research and strategic commercialization. This news hub provides investors and healthcare professionals with essential updates on the biopharmaceutical leader's clinical developments, regulatory milestones, and market activities.

Track all critical DVAX updates in one place: Access press releases covering vaccine trial progress, FDA decisions, financial results, and partnership announcements. Our curated feed includes updates on HEPLISAV-B commercialization, CpG 1018 adjuvant applications, and pipeline developments across infectious disease and cancer immunotherapy programs.

Key coverage areas: Regulatory submissions for new vaccine candidates, quarterly earnings reports, manufacturing expansions, and scientific presentations. Content is rigorously verified to ensure accuracy for both professional investors and those monitoring public health advancements.

Bookmark this page for continuous access to Dynavax's official communications and analysis of strategic initiatives shaping the future of preventive healthcare. Check regularly for developments impacting vaccine accessibility and immunological innovation.

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) has initiated a Phase 1/2 clinical trial of its investigational shingles vaccine, Z-1018. The study will assess the vaccine’s safety, tolerability, and immunogenicity in approximately 440 healthy adults aged 50-69 years in Australia. Z-1018, which uses the CpG 1018 adjuvant, aims to provide improved tolerability and strong CD4+ T-cell responses compared to the market-leading Shingrix® vaccine. The trial will determine the optimal dose and schedule for future studies and validate a Patient Reported Outcome measurement tool for differentiating Z-1018 on tolerability. Top-line results are expected in the second half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
-
Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, will present at two investor conferences in June 2024. The company will participate in the William Blair 44th Annual Growth Stock Conference on June 4 at 1:20 PM CT and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 PM ET. Webcasts of these presentations will be accessible on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences
-
Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) announced that the U.S. FDA has issued a Complete Response Letter (CRL) regarding its supplemental Biologics License Application (sBLA) for a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis. The CRL cited insufficient data to fully evaluate the effectiveness and safety of the regimen, due to the destruction of data source documents and an inadequate sample size in the HBV-24 study. This decision does not impact the current approved indications for HEPLISAV-B in the U.S., EU, and Great Britain, nor the European Commission's approval of the four-dose regimen for hemodialysis patients. Dynavax plans to meet with the FDA to explore options for providing additional data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
Rhea-AI Summary

Dynavax reported $48 million in HEPLISAV-B vaccine net product revenue, a 10% increase year-over-year in Q1 2024. The company reaffirmed its full-year revenue guidance and FDA clearance to initiate Phase 1/2 trial of Z-1018 shingles program. Dynavax continues to evaluate strategic growth opportunities while focusing on expanding its hepatitis B vaccine market share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
-
Rhea-AI Summary
Dynavax Technologies (DVAX) will report its first quarter 2024 financial results on May 8, 2024, after the U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT. Participants can access the webcast through the 'Events & Presentations' page on the Company's website. A replay will be available for 30 days. To join the call, participants need to register using the caller registration link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
conferences earnings
-
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) to present at TD Cowen's 44th Annual Health Care Conference on March 4, 2024, at 10:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) reports a strong financial performance for the fourth quarter and full year 2023, with HEPLISAV-B vaccine net product revenue growing by 69% year-over-year to $213 million. Achieving market leader status in key segments and expecting a revenue of $265 - $280 million in 2024, the company is well-positioned for growth and innovation in the vaccine market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
-
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) will report its Q4 and full year 2023 financial results on February 22, 2024, after the U.S. financial markets close. The company will also host a conference call and live audio webcast on the same day. The live audio webcast can be accessed through the 'Events & Presentations' page on the 'Investors' section of the Company's website. A replay of the webcast will be available for 30 days. Participants can register for the call using the caller registration link and are recommended to dial in or log into the webcast 10 minutes prior to the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences earnings
-
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) reports a 69% year-over-year increase in HEPLISAV-B vaccine net product revenue to approximately $213 million for the full year 2023. The company also saw significant gains in HEPLISAV-B market share in the U.S., with total market share increasing to approximately 44% compared to approximately 35% at the end of 2022. Cash, cash equivalents, and marketable securities at year-end increased to approximately $742 million, with the expectation to be cash flow positive for the full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
none
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
Dynavax Technolo

Nasdaq:DVAX

DVAX Rankings

DVAX Stock Data

1.42B
121.70M
0.48%
107.55%
15.26%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
EMERYVILLE